Literature DB >> 22262484

Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.

Carolina Cannillo Graffe1, Jesper Nørgaard Bech, Thomas Guldager Lauridsen, Erling Bjerregaard Pedersen.   

Abstract

Renal handling of sodium and water is abnormal in chronic kidney diseases. To study the function and regulation of the aquaporin-2 water channel (AQP2) and the epithelial sodium channel (ENaC) in autosomal dominant polycystic kidney disease (ADPKD), we measured urinary excretion of AQP2 (u-AQP2), the β-subunit of ENaC (u-ENaC(β)), cAMP (u-cAMP), and prostaglandin E(2) (u-PGE(2)); free water clearance (C(H2O)); fractional sodium excretion (FE(Na)); and plasma vasopressin (p-AVP), renin (p-Renin), angiotensin II (p-ANG II), aldosterone (p-Aldo), and atrial and brain natriuretic peptide (p-ANP, p-BNP) in patients with ADPKD and healthy controls during 24-h urine collection and after hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day) and low sodium intake (LS; 30 mmol sodium/day). No difference in u-AQP2, u-ENaC(β), u-cAMP, u-PGE(2), C(H2O), and vasoactive hormones was found between patients and controls at baseline, but during HS the patients had higher FE(Na). The saline caused higher increases in FE(Na) in patients than controls during LS, but the changes in u-ENaC(β), p-Aldo, p-ANP, p-BNP, p-Renin, and p-ANG II were similar. Higher increases in u-AQP2 and p-AVP were seen in patients during both diets. In conclusion, u-AQP2 and u-ENaC(β) were comparable in patients with ADPKD and controls at baseline. In ADPKD, the larger increase in u-AQP2 and p-AVP in response to saline could reflect an abnormal water absorption in the distal nephron. During LS, the larger increase in FE(Na) in response to saline could reflect a defective renal sodium retaining capacity in ADPKD, unrelated to changes in u-ENaC(β).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262484     DOI: 10.1152/ajprenal.00616.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

1.  Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.

Authors:  Murali K Yanda; Boyoung Cha; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

2.  Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Akiko Nakajima; Yan Lu; Haruna Kawano; Shigeo Horie; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2015-02-27       Impact factor: 2.801

Review 3.  Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases.

Authors:  Emma T B Olesen; Robert A Fenton
Journal:  Nat Rev Nephrol       Date:  2021-07-01       Impact factor: 28.314

4.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

5.  Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.

Authors:  Safa Al Therwani; My Emma Sofie Malmberg; Jeppe Bakkestroem Rosenbaek; Jesper Noergaard Bech; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2017-08-15       Impact factor: 2.388

6.  Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD.

Authors:  Shiho Makabe; Shun Manabe; Hiroshi Kataoka; Taro Akihisa; Rie Yoshida; Yusuke Ushio; Masayo Sato; Ken Tsuchiya; Toshio Mochizuki; Kosaku Nitta
Journal:  Kidney Int Rep       Date:  2021-07-14

Review 7.  Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.

Authors:  Rhubaniya Mahendran; Soo Kun Lim; Kien Chai Ong; Kek Heng Chua; Hwa Chia Chai
Journal:  Clin Exp Nephrol       Date:  2021-07-12       Impact factor: 2.801

8.  Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-06-26       Impact factor: 2.388

Review 9.  CPT-cGMP Is A New Ligand of Epithelial Sodium Channels.

Authors:  Hong-Long Ji; Hong-Guang Nie; Yongchang Chang; Qizhou Lian; Shan-Lu Liu
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

10.  Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Annette T Y Wong; Alexandra Munt; Margaret Allman-Farinelli; Sunil V Badve; Neil Boudville; Helen Coolican; Ashley N Chandra; Susan Coulshed; Mangalee Fernando; Jared Grantham; Imad Haloob; David C H Harris; Carmel M Hawley; Jane Holt; David W Johnson; Karthik Kumar; Vincent W Lee; Maureen Lonergan; Jun Mai; Anna Rangan; Simon D Roger; Sayanthooran Saravanabavan; Kamal Sud; Vicente E Torres; Eswari Vilayur; Jennifer Q J Zhang; Gopala K Rangan
Journal:  Nutrients       Date:  2020-11-02       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.